Cyclomics

Executive Summary

Cyclomics is a Netherlands-based precision diagnostics company pioneering ultra-sensitive liquid biopsy for cancer detection and monitoring. Its core innovation combines consensus sequencing with Oxford Nanopore's platform, enabling direct detection of rare mutations from blood samples with unprecedented accuracy. This approach addresses key limitations of current liquid biopsy technologies, such as high error rates and limited sensitivity, by leveraging a unique consensus error-correction method that filters out sequencing noise. Cyclomics targets early cancer detection, minimal residual disease monitoring, and personalized treatment guidance, positioning itself as a transformative player in molecular diagnostics. Founded in 2018, the company is privately held and actively advancing its technology toward clinical validation. As an early-stage diagnostics innovator, Cyclomics has the potential to disrupt the oncology liquid biopsy market, projected to exceed $10 billion by 2030. Its differentiation lies in the use of nanopore sequencing, which offers real-time, scalable, and cost-effective analysis compared to NGS-based competitors. While the company has not disclosed funding or revenue, its focus on accessible molecular diagnostics aligns with growing demand for non-invasive cancer management. Key risks include technical validation in larger cohorts and competition from established players like Guardant Health and Grail. Nonetheless, Cyclomics' novel platform could capture significant value if clinical performance is proven.

Upcoming Catalysts (preview)

• Q4 2026Publication of clinical validation study in liquid biopsy for early-stage cancer70% success
• H1 2027Strategic partnership with pharmaceutical company for drug monitoring applications60% success
• Q3 2026Completion of Series A funding round to support regulatory submissions80% success